Safety and Efficacy of Exclusive Enteral Nutrition for Percutaneously Undrainable Abdominal Abscesses in Crohn’s Disease

Table 2

Univariate analysis of potential predictors for surgery in CD patients with percutaneously undrainable abscesses.

Variable	1-year cumulative surgical rate (%)	(log-rank)
Gender		0.972
Male	87.2
Female	83.3
Age at diagnosis		0.895
A1 (16 years)	0
A2 (17–40 years)	86.2
A3 (40 years)	84.0
Disease location		0.208
L1 (ileal)	85.7
L2 (colonic)	100.0
L3 (ileocolonic)	84.6
Steroids use at diagnosis		0.703
No	86.3
Yes	84.4
AZA/6-MP use at diagnosis		0.550
No	89.8
Yes	79.4
Infliximab use at diagnosis		0.360
No	87.7
Yes	70.0
Perianal lesion		0.922
No	85.5
Yes	85.7
Previous abdominal surgery		0.007
No	81.2
Yes	100.0
Abscess diameter > 3 cm		0.006
No	80.3
Yes	100
Fistula		0.928
No	85.4
Yes	85.7
Multiple abscesses		0.060
No	82.4
Yes	100
Abscess location		0.253
Right lower quadrant	83.8
Pelvis	88.0
Others	85.7
Exclusive enteral nutrition		0.001
No	96.6
Yes	79.6

AZA: azathioprine; 6-MP: mercaptopurine.